Vectura Share Discussion Threads

[pooroldboy55] 07/11/2017 09:26

Agree and not a word from CEO or DIRECTOR'S about share price halving in 12 months.
again today price drop follows O trade

[cumnor] 07/11/2017 09:15

Main problem here is a weak, uninspiring CEO. Plenty of solid, secure income streams that enable profitability and huge potential in IP and technology (advair is not the bee all and end all-it is another generic drug which may or may not come on-it should with proper handling of the FDA concerns-but an enterprising CEO would be way ahead of that game with other products, tie ups etc and not allow the share price be held hostage to fortune by the markets fixation on a relatively minor issue like advair. It's confidence and up to the CEO, and down to him as well. imo

[a1ord53] 07/11/2017 09:00

Alexchry, I bought VEC because all analysts like Numis , JPMorgan , PEEL HUNT were and being giving 160-200p targets . Also value of Advair were estimated 20p for each share.
Advairs stripped 60p of share price
So the analysts created bare trap for investors like myself.
Management doing nothing to establish trust worthy relationships with investors and merger with SKP is disaster for both shareholders sides.
You right that some unexpected good news could push share price - but this news should be ad value and not just promises .
I think management and analysts are corrupt and its why recommendantations and target prices are so high and have not substance.

[alexchry] 07/11/2017 08:26

RogerRail-pleasing to know that Flutiform is meeting sales forecasts in Japan with a 20% increase but what we need is some unexpected good news to give the share price a kick up the backside.

[rogerrail] 06/11/2017 21:35

Flutiform sales in Japan meeting expectations with near 20%increase in H1 revenue and on target to hit Y12 billion sales v 10.1 last year

[pooroldboy55] 06/11/2017 13:55

Yes will go along with that.

[dp1umb] 06/11/2017 13:32

Should of kept my big mouth closed!! But
POORBOY btg’s fall comes after a couple of months of good gains vectura has been down hill all the way.

[alexchry] 06/11/2017 08:28

pob-not looked at the trades, just the sinking share price My only hope is that the regulatory timetable is published before the end of the year and gives some optimism for the eventual approval of the Advair generic.

[dp1umb] 03/11/2017 17:26

Except BTG £££;££££

[citytrader66] 03/11/2017 17:01

friday often a poor day for shares and no different today. nearly every share in red today. VEC held up quite well really.

[pooroldboy55] 03/11/2017 16:25

Hi Alex have you noticed price tends to go down when there's a O trade ?

[alexchry] 03/11/2017 14:46

cont. share price has more than halved and the VEC share price has nearly done the same. It seems the market has little confidence in approval coming anytime soon. The regulatory timetable is due to be published by the end of the year, let's hope it's good news.

[alexchry] 03/11/2017 14:41

It does seem to me that the Advair generic being knocked back has been responsible for most of the fall. The Hikma

[pooroldboy55] 03/11/2017 12:40

Hate to say it but still think heading into the 80s. Usually when I say this the price goes up here's hoping.

[popper joe] 01/11/2017 12:46

The GSK RNS from today makes reference to a company named Innoviva and credits that company with joint development of Anora Ellipta. It also mentions Innoviva's ongoing rights to royalties. A quick look at Innoviva's web site and a click on their "Portfolio" shows only 3 products: Anora Ellipta, Breo Ellipta and Relvar Ellipta. Those are the 3 products that Vectura are in dispute over. All seems a bit suspicious to me. Any one else have a view?

[alexchry] 01/11/2017 12:41

I got the impression that this was competition for VEC as GSK are using another company, Innoviva, for Anoro Ellipta so not good news for VEC.

[pooroldboy55] 01/11/2017 11:34

will they use VEC's tec?

[fhmktg] 01/11/2017 11:16

Maybe they were aware of the GSK announcement on Anoro Ellipta for copd?Presumably this uses VEC technology?

[pooroldboy55] 01/11/2017 10:32

Did anyone else notice the price spiked before RNS then fell back after,perhaps they were expecting some good news but for sure they knew a RNS was on its way !!!!

[fhmktg] 27/10/2017 15:31

Hard to see where the good news is going to come from....Jury trial date is late 2018....update on the fda CP program might indicate the launch in time for the 2018/9 season.The budenoside trial isn't due to report until late 2018.We might see some cash in from Sandoz, but only growth in Flutiform and perhaps some extended clinical areas...Any areas of optimism that I've missed?

[sikhthetech] 27/10/2017 15:05

I also here via skp.. I agree with some of the comments...

I've sold a few to invest elsewhere for now... will monitor and look at re-buying the one's I sold...

[0815exitstrategy] 27/10/2017 14:39

I came in with Vec which did great until SKP came in.... ;-)
e.g. VEC share price was pushed down shortly prior to merger so SKP got more shares.

[pooroldboy55] 27/10/2017 14:38

I see the 1250 still going though